Hsieh A - Search Results

1

The burden of familial chylomicronemia syndrome from the patients' perspective.

Gelrud A, Williams KR, Hsieh A, Gwosdow AR, Gilstrap A, Brown A. Gelrud A, et al. Among authors: hsieh a. Expert Rev Cardiovasc Ther. 2017 Nov;15(11):879-887. doi: 10.1080/14779072.2017.1372193. Epub 2017 Sep 11. Expert Rev Cardiovasc Ther. 2017. PMID: 28847199

2

The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study.

Davidson M, Stevenson M, Hsieh A, Ahmad Z, Crowson C, Witztum JL. Davidson M, et al. Among authors: hsieh a. Expert Rev Cardiovasc Ther. 2017 May;15(5):415-423. doi: 10.1080/14779072.2017.1311786. Epub 2017 Apr 4. Expert Rev Cardiovasc Ther. 2017. PMID: 28338353

3

The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study.

Arca M, Hsieh A, Soran H, Rosenblit P, O'Dea L, Stevenson M. Arca M, et al. Among authors: hsieh a. Expert Rev Cardiovasc Ther. 2018 Jul;16(7):537-546. doi: 10.1080/14779072.2018.1487290. Epub 2018 Jun 22. Expert Rev Cardiovasc Ther. 2018. PMID: 29889589

4

The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study.

Davidson M, Stevenson M, Hsieh A, Ahmad Z, Roeters van Lennep J, Crowson C, Witztum JL. Davidson M, et al. Among authors: hsieh a. J Clin Lipidol. 2018 Jul-Aug;12(4):898-907.e2. doi: 10.1016/j.jacl.2018.04.009. Epub 2018 Apr 26. J Clin Lipidol. 2018. PMID: 29784572 Free article.

5

Development of a novel PRO instrument for use in familial chylomicronemia syndrome.

Davidson D, Slota C, Vera-Llonch M, Brown TM, Hsieh A, Fehnel S. Davidson D, et al. Among authors: hsieh a. J Patient Rep Outcomes. 2021 Aug 11;5(1):72. doi: 10.1186/s41687-021-00347-5. J Patient Rep Outcomes. 2021. PMID: 34382114 Free PMC article.

6

PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.

Edlind MP, Hsieh AC. Edlind MP, et al. Asian J Androl. 2014 May-Jun;16(3):378-86. doi: 10.4103/1008-682X.122876. Asian J Androl. 2014. PMID: 24759575 Free PMC article. Review.

7

The translational landscape of mTOR signalling steers cancer initiation and metastasis.

Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, Wang S, Ren P, Martin M, Jessen K, Feldman ME, Weissman JS, Shokat KM, Rommel C, Ruggero D. Hsieh AC, et al. Nature. 2012 Feb 22;485(7396):55-61. doi: 10.1038/nature10912. Nature. 2012. PMID: 22367541 Free PMC article.

8

Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors.

Hsieh AC, Nguyen HG, Wen L, Edlind MP, Carroll PR, Kim W, Ruggero D. Hsieh AC, et al. Sci Signal. 2015 Nov 17;8(403):ra116. doi: 10.1126/scisignal.aad5111. Sci Signal. 2015. PMID: 26577921 Free PMC article.

9

A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer.

Wei XX, Hsieh AC, Kim W, Friedlander T, Lin AM, Louttit M, Ryan CJ. Wei XX, et al. Oncologist. 2017 May;22(5):503-e43. doi: 10.1634/theoncologist.2016-0432. Epub 2017 Mar 17. Oncologist. 2017. PMID: 28314838 Free PMC article. Clinical Trial.

10

Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development.

Hsieh AC, Small EJ, Ryan CJ. Hsieh AC, et al. Lancet Oncol. 2007 Oct;8(10):933-9. doi: 10.1016/S1470-2045(07)70316-9. Lancet Oncol. 2007. PMID: 17913662 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

490 results

Search Page